Evidence map›Paper›PMID 21842473›Full record

ReviewAdvanced materials (Deerfield Beach, Fla.)2011

Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers.

Forrest M Kievit, Miqin Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced materials (Deerfield Beach, Fla.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers.

0numbers the graph read from it
0cells of the map it votes in
122citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

122 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

62 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Forrest M KievitDepartment of Materials Science and Engineering, University of Washington, Seattle, WA 98195, USA.
Miqin Zhang

Funding

Multifuctional Nanovector For Diagnosis And Treatment Of Pediatric Brain CancerR01EB006043 · NIBIB · UNIVERSITY OF WASHINGTON · PI ZHANG, MIQIN · 2007 to 2010
$1.6M
Nanotechnology and Physical Science Training Program in Cancer ResearchT32CA138312 · NCI · UNIVERSITY OF WASHINGTON · PI ZHANG, MIQIN · 2009 to 2013
$1.5M
Nanovectors For Brain Tumor Diagnosis And TreatmentR01CA134213 · NCI · UNIVERSITY OF WASHINGTON · PI ZHANG, MIQIN · 2007 to 2011
$1.5M
NCI NIH HHS R01 CA134213NCI NIH HHS R01CA134213NCI NIH HHS T32 CA138312NCI NIH HHS T32CA138312NIBIB NIH HHS R01 EB006043NIBIB NIH HHS R01EB006043
6 · The paper itself

Abstract

Cancer nanotheranostics aims to combine imaging and therapy of cancer through use of nanotechnology. The ability to engineer nanomaterials to interact with cancer cells at the molecular level can significantly improve the effectiveness and specificity of therapy to cancers that are currently difficult to treat. In particular, metastatic cancers, drug-resistant cancers, and cancer stem cells impose the greatest therapeutic challenge for targeted therapy. Targeted therapy can be achieved with appropriately designed drug delivery vehicles such as nanoparticles, adult stem cells, or T cells in immunotherapy. In this article, we first review the different types of nanotheranostic particles and their use in imaging, followed by the biological barriers they must bypass to reach the target cancer cells, including the blood, liver, kidneys, spleen, and particularly the blood-brain barrier. We then review how nanotheranostics can be used to improve targeted delivery and treatment of cancer cells. Finally, we discuss development of nanoparticles to overcome current limitations in cancer therapy.

Indexed as

AnimalsDiagnostic ImagingDrug Delivery SystemsHumansNanomedicineNeoplasms

Identifiers

PMID21842473
PMCPMC3397249

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.